Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Genital Herpes Treatment Market 2022
Genital herpes is a common sexually transmitted infection caused by the herpes simplex virus (HSV). It causes herpetic sores, which are painful blisters (fluid-filled bumps) that can break open and ooze fluid. Two types of the herpes simplex virus (HSV) cause genital herpes: HSV-1 and HSV-2. The World Health Organization stated that in 2016, about 3.7 billion people under age 50 years had contracted HSV-1. In the same year, around 491 million people ages 15 to 49 years had an HSV-2 infection. A study by StrategyHelix indicates that the global genital herpes treatment market is expected to increase by US$ 580.4 million from 2022 to 2028, garnering a CAGR of 4.1% during the forecast period.
The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for genital herpes treatment. The global genital herpes treatment market is segmented on the basis of product, virus type, route of administration, distribution channel, and region. Based on product, the global genital herpes treatment market is categorized into acyclovir, famciclovir, valacyclovir, others. Globally, the acyclovir segment made up the largest share of the genital herpes treatment market. On the basis of virus type, the global genital herpes treatment market has been segmented into HSV-1, HSV-2. By route of administration, the global genital herpes treatment market has been segmented into injection, oral, topical. According to the research, the oral segment had the largest share in the global genital herpes treatment market. Based upon distribution channel, the global genital herpes treatment market is categorized into hospitals, online pharmacies, pharmacies & drug stores. In terms of geography, the global genital herpes treatment market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).
The global genital herpes treatment market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players Abbott Laboratories, Avet Pharmaceuticals Inc., Bausch Health Companies Inc., Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, GSK plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the genital herpes treatment market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Product: acyclovir, famciclovir, valacyclovir, others
Virus type: HSV-1, HSV-2
Route of administration: injection, oral, topical
Distribution channel: hospitals, online pharmacies, pharmacies & drug stores
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028
Key Benefits for Stakeholders
– Get a comprehensive picture of the global genital herpes treatment market
– Pinpoint growth sectors and trends for investment
Table of Contents
Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Genital herpes treatment market overview
Part 3. Market breakdown by product
Part 4. Market breakdown by virus type
Part 5. Market breakdown by route of administration
Part 6. Market breakdown by distribution channel
– Online pharmacies
– Pharmacies & drug stores
Part 7. Market breakdown by region
– North America
– Asia Pacific
– Rest of the World (ROW)
Part 8. Key companies
– Abbott Laboratories
– Avet Pharmaceuticals Inc.
– Bausch Health Companies Inc.
– Cipla Limited
– Eli Lilly and Company
– Glenmark Pharmaceuticals Limited
– GSK plc
– Novartis AG
– Pfizer Inc.
– Teva Pharmaceutical Industries Ltd.
– Viatris Inc.